KR920701136A - 아릴-및 헤테로아릴에테닐렌 유도체 및 이의 제조방법 - Google Patents

아릴-및 헤테로아릴에테닐렌 유도체 및 이의 제조방법

Info

Publication number
KR920701136A
KR920701136A KR1019910701435A KR910701435A KR920701136A KR 920701136 A KR920701136 A KR 920701136A KR 1019910701435 A KR1019910701435 A KR 1019910701435A KR 910701435 A KR910701435 A KR 910701435A KR 920701136 A KR920701136 A KR 920701136A
Authority
KR
South Korea
Prior art keywords
cyano
acrylamide
tetrahydronaphth
hydroxy
hydroxyquinolin
Prior art date
Application number
KR1019910701435A
Other languages
English (en)
Inventor
부제티 프랑코
롱고 안토니오
콜롬보 마리스텔라
Original Assignee
비토리노 페라리오
팜이탈리아 카를로 에르바 에스. 알. 엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비토리노 페라리오, 팜이탈리아 카를로 에르바 에스. 알. 엘 filed Critical 비토리노 페라리오
Publication of KR920701136A publication Critical patent/KR920701136A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/40—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/36—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/44—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Catalysts (AREA)

Abstract

내용 없음

Description

아릴-및 헤테로아릴에테닐렌 유도체 및 이의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 일반식(I)의 화합물 및 약제학적으로 허용되는 이의 염.
    상기식에서, Y는 (A), (B),(c), (D), (E), (F) 및 (G)중에서 선택된 모노-또는 비사이클릭 환 시스템이고,
    R은 (a), (b), (c), (d), (e), (f), (g), (h), (i) 또는 (j)의 그룹이고,
    R3은 -OH 또는 -NH2이고, Ph는 페닐이고, R1은 수소, C1-C6알킬 또는 C2-C6알카노일이고, R2는 수소, 할로겐, 시아노 또는 C1-C6알킬이고, n은 0 또는 1 내지 3의 정수이고, Y가 환 시스템(A)인 경우 n은 0 또는 1 내지 3의 정수이고; Y가 환 시스템(B), (E), (F) 또는 (G)인 경우 n은 0, 1 또는 2이고; Y가 환 시스템(C) 또는 (D)인 경우 n은 0 또는 1이고, 치환체 R, OR1및 R2의 각각은 독립적으로 비사이클릭 환 시스템(A), (E), (F) 및 (G)의 아릴이거나 헤테로아릴 잔기일 수 있으며, 벤젠 잔기만이 비사이클릭 환시스템(B)에서 치환될 수 있다.
  2. 제1항에 있어서, Y가 모모사이클릭 또는 비사이클릭 환 시스템(A) 내지 (G) 중에서 선택되며; R이 (a), (b), (c), (d), (e), (i) 또는 (j)의 그룹이고; R1이 수소, C1-C4알킬 또는 C2-C4알카노일이고; R2가 수소이고; n이 제1항에서 정의한 바와 같은 일반식(I)의 화합물 및 약제학적으로 허용되는 이의 염.
  3. 제1항에 있어서, Y가 일반식(A), (B) 또는 (E)의 비사이클릭 환 시스템이고; R이 (a), (d), (e), (i) 또는 (j)의 그룹이고, R1및 R2가 수소이고; n이 0 또는 1인 일반식(I)의 화합물 및 약제학적으로 허용되는 이의 염.
  4. Z- 또는 E-부분입체이성체 또는 부분입체이성체의 혼합물일 수 있는, 2-시아노-3-(2-하이드록시나프트-1-일)아크릴아미드; 2-시아노-3-(3-하이드록시나프트-1-일)아크릴아미드; 2-시아노-3-(4-하이드록시나프트-1-일)아크릴아미드; 2-시아노-3-(1-하이드록시나프트-1-일)아크릴아미드; 2-시아노-3-(3-하이드록시나프트-2-일)아크릴아미드; 2-시아노-3-(4-하이드록시나프트-2-일)아크릴아미드; 2-시아노-3-(2-하이드록시나프트-1-일)아크릴산; 2-시아노-3-(3-하이드록시나프트-1-일)아크릴산; 2-시아노-3-(4-하이드록시나프트-1-일)아크릴산; 2-시아노-3-(1-하이드록시나프트-2-일)아크릴산; 2-시아노-3-(3-하이드록시나프트-2-일)아크릴산; 2-시아노-3-(4-하이드록시나프트-2-일)아크릴산; 2-시아노-3-(2-하이드록시나프트-1-일)티오아크릴아미드; 2-시아노-3-(3-하이드록시나프트-1-일)티오아크릴아미드; 2-시아노-3-(4-하이드록시나프트-1-일)티오아크릴아미드; 2-시아노-3-(1-하이드록시나프트-2-일)티오아크릴아미드; 2-시아노-3-(3-하이드록시나프트-2-일)티오아크릴아미드; 2-시아노-3-(4-하이드록시나프트-2-일)티오아크릴아미드; 2-(4-하이드록시페닐)-3-(나프트-1-일)아크릴아미드; 2-(4-하이드록시페닐)-3-(나프트-2-일)아크릴아미드; 2-(4-하이드록시페닐)-3-(나프트-1-일)아크릴산; 2-(4-하이드록시페닐)-3-(나프트-2-일)아크릴산; 2-시아노-3-(2-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)아크릴아미드; 2-시아노-3-(3-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)아크릴아미드; 2-시아노-3-(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)아크릴아미드; 2-시아노-3-(1-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)아크릴아미드; 2-시아노-3-(3-하이드록시나프트-5,6,7,8-테트라하이드로나프트-2-일)아크릴아미드; 2-시아노-3-(4-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)아크릴아미드; 2-시아노-3-(2-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)아크릴산; 2-시아노-3-(3-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)아크릴산; 2-시아노-3-(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)아크릴산; 2-시아노-3-(1-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)아크릴산; 2-시아노-3-(3-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)아크릴산; 2-시아노-3-(4-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)아크릴산; 2-시아노-3-(2-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)티오아크릴아미드; 2-시아노-3-(3-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)티오아크릴아미드; 2-시아노-3-(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)티오아크릴아미드; 2-시아노-3-(1-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)티오아크릴아미드; 2-시아노-3-(3-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)티오아크릴아미드; 2-시아노-3-(4-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)티오아크릴아미드; 2-(4-하이드록시페닐)-3-(5,6,7,8-테트라하이드로나프트-1-일)아크릴아미드; 2-(4-하이드록시페닐)-3-(5,6,7,8-테트라하이드로나프트-2-일)아크릴아미드; 2-(4-하이드록시페닐)-3-(5,6,7,8-테트라하이드로나프트-1-일)아크릴아미드; 2-(4-하이드록시페닐)-3-(5,6,7,8-테트라하이드로나프트-2-일)아크릴아미드; 2-시아노-3-(3-하이드록시퀴놀린-2-일)아크릴아미드; 2-시아노-3-(4-하이드록시퀴놀린-2-일)아크릴아미드; 2-시아노-3-(2-하이드록시퀴놀린-3-일)아크릴아미드; 2-시아노-3-(4-하이드록시퀴놀린-3-일)아크릴아미드; 2-시아노-3-(2-하이드록시퀴놀린-4-일)아크릴아미드; 2-시아노-3-(3-하이드록시퀴놀린-4-일)아크릴아미드; 2-시아노-3-(3-하이드록시퀴놀린-2-일)아크릴산; 2-시아노-3-(4-하이드록시퀴놀린-2-일)아크릴산; 2-시아노-3-(2-하이드록시퀴놀린-3-일)아크릴산; 2-시아노-3-(4-하이드록시퀴놀린-3-일)아크릴산; 2-시아노-3-(2-하이드록시퀴놀린-4-일)아크릴산; 2-시아노-3-(3-하이드록시퀴놀린-4-일)아크릴산; 2-시아노-3-(3-하이드록시퀴놀린-2-일)티오아크릴아미드; 2-시아노-3-(3-하이드록시퀴놀린-2-일)티오아크릴아미드; 2-시아노-3-(2-하이드록시퀴놀린-3-일)티오아크릴아미드; 2-시아노-3-(3-하이드록시퀴놀린-2-일)티오아크릴아미드; 2-시아노-3-(4-하이드록시퀴놀린-3-일)티오아크릴아미드; 2-시아노-3-(2-하이드록시퀴놀린-4-일)티오아크릴아미드; 2-시아노-3-(3-하이드록시퀴놀린-4-일)티오아크릴아미드; 2-(4-하이드록시페닐)-3-(퀴놀린-2-일)아크릴아미드; 2-(4-하이드록시페닐)-3-(퀴놀린-3-일)아크릴아미드; 2-(4-하이드록시페닐)-3-(퀴놀린-4-일)아크릴아미드; 2-(4-하이드록시페닐)-3-(퀴놀린-2-일)아크릴산; 2-(4-하이드록시페닐)-3-(퀴놀린-3-일)아크릴산; 2-(4-하이드록시페닐)-3-(퀴놀린-4-일)아크릴산; 3-[(3-하이드록시-1-나프틸)메틸렌]-2-옥스인돌; 3-[(4-하이드록시-1-나프틸)메틸렌]-2-옥스인돌; 3-[(1-하이드록시-2-나프틸)메틸렌]-2-옥스인돌; 3-[(4-하이드록시-2-나프틸)메틸렌]-2-옥스인돌; 3-[(3-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)메틸렌]-2-옥스인돌; 3-[(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)메틸렌]-2-옥스인돌; 3-[(1-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)메틸렌]-2-옥스인돌; 3-[(4-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)메틸렌]-2-옥스인돌; 3-[(7-하이드록시퀴놀린-5-일)메틸렌]-2-옥스인돌; 3-[(8-하이드록시퀴놀린-5-일)메틸렌]-2-옥스인돌; 3-[(7-하이드록시퀴놀린-6-일)메틸렌]-2-옥스인돌; 3-[(8-하이드록시퀴놀린-6-일)메틸렌]-2-옥스인돌, 및 약제학적으로 허용되는 이의 염중에서 선택되는 화합물.
  5. 일반식(Ⅱ)의 알데이드를 각각 일반식(a'), (b'), (c'), (d'), (e'), (f'), (g'), (h') (i') 또는 (j')와 축합시키고, 필요한 경우 일반식(I)의 화합물을 다른 일반식(I)의 화합물로 전환시키고/시키거나, 필요한 경우 일반식(I)의 화합물을 약제학적으로 허용되는 이의 염으로 전환시키고/시키거나, 필요한 경우 일반식(I)의 화합물의 이성체 혼합물을 단일 이성체로 분리시킴을 특징으로 하여 일반식(I)의 화합물 또는 약제학적으로 허용되는 이의 염을 제조하는 방법.
    상기식에서, R1, R2, R3, Y 및 Ph는 제1항에서 정의한 바와 같다.
  6. 활성성분으로서 제1항에 따른 일반식(I)의 화합물 또는 약제학적으로 허용되는 이의 염과 적당한 담체 및/또는 희석제를 함유하는 약제학적 조성물.
  7. 타이로신 키나제 억제제로서 사용하기 위한, 제1항에 따른 일반식(I)의 화합물 또는 약제학적으로 허용되는 이의 염.
  8. 약제의 제조에서 타이로신 커나제 억제제로서 사용하기 위한, 제1항에서 정의한 일반식(I)의 화합물 또는 약제학적으로 허용되는 이의 염의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910701435A 1990-02-28 1991-02-26 아릴-및 헤테로아릴에테닐렌 유도체 및 이의 제조방법 KR920701136A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB90044835 1990-02-28
GB909004483A GB9004483D0 (en) 1990-02-28 1990-02-28 New aryl-and heteroarylethenylene derivatives and process for their preparation
PCT/EP1991/000350 WO1991013055A2 (en) 1990-02-28 1991-02-26 New aryl- and heteroarylethenylene derivatives and process for their preparation

Publications (1)

Publication Number Publication Date
KR920701136A true KR920701136A (ko) 1992-08-11

Family

ID=10671744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701435A KR920701136A (ko) 1990-02-28 1991-02-26 아릴-및 헤테로아릴에테닐렌 유도체 및 이의 제조방법

Country Status (20)

Country Link
US (3) US5374652A (ko)
EP (2) EP0662473B1 (ko)
JP (2) JP3152434B2 (ko)
KR (1) KR920701136A (ko)
AT (2) ATE131470T1 (ko)
CA (1) CA2053253C (ko)
DE (2) DE69115379T2 (ko)
DK (1) DK0470221T3 (ko)
ES (2) ES2083569T3 (ko)
FI (1) FI915010A0 (ko)
GB (1) GB9004483D0 (ko)
GR (1) GR3018891T3 (ko)
HU (1) HU210791B (ko)
IE (1) IE73666B1 (ko)
IL (1) IL97049A (ko)
NZ (1) NZ237182A (ko)
PT (1) PT96897B (ko)
RU (1) RU2091369C1 (ko)
WO (1) WO1991013055A2 (ko)
ZA (1) ZA911441B (ko)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
CA2080582A1 (en) * 1990-04-16 1991-10-17 Alfred P. Spada Heterocyclicethenediyl compounds which inhibit egf receptor tyrosine kinase
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
EP0549348A1 (en) * 1991-12-24 1993-06-30 PHARMACIA S.p.A. Arylidene-heterocyclic derivatives, process for their preparation and their use as tyrisine kinase inhibitors
US5587385A (en) * 1991-12-24 1996-12-24 Farmitalia Carlo Erba S.R.L. Arylidene-heterocyclic derivatives and process for their preparation
GB9204945D0 (en) * 1992-03-06 1992-04-22 Erba Carlo Spa 3-aryl-glycidic ester derivatives and process for their preparation
CZ283965B6 (cs) * 1992-08-06 1998-07-15 Warner-Lambert Company 2-thioindolové, 2-indolinthionové a polysulfidové sloučeniny, 2-selenoindolové, 2-indolinselenonové a selenidové sloučeniny a farmaceutické prostředky na jejich bázi
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
US5449788A (en) * 1994-01-28 1995-09-12 Catalytica, Inc. Process for preparing 2-oxindole-1-carboxamides
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) * 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9610964D0 (en) * 1996-05-24 1996-07-31 Pharmacia & Upjohn Spa Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
GB9611797D0 (en) * 1996-06-06 1996-08-07 Pharmacia Spa Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
EP1247803A3 (en) * 1996-08-23 2002-10-16 Sugen, Inc. Indolinone compounds suitable for modulation of protein kinases
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
WO1998024432A2 (en) * 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6159978A (en) 1997-05-28 2000-12-12 Aventis Pharmaceuticals Product, Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
HUP0004807A3 (en) * 1997-05-28 2001-12-28 Aventis Pharma Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them
US6180632B1 (en) 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6051593A (en) 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US20040067531A1 (en) * 1997-08-20 2004-04-08 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
WO2000008202A2 (en) * 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
CA2321307A1 (en) 1998-02-27 1999-09-02 Venkatachala L. Narayanan Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
AU3363599A (en) * 1998-03-26 1999-10-18 Max-Planck Institut Fur Biochemie Heterocyclic families of compounds for the modulation of tyrosine protein kinase
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
SK287132B6 (sk) 1998-05-29 2009-12-07 Sugen, Inc. Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
KR20010101266A (ko) 1998-12-17 2001-11-14 프리돌린 클라우스너, 롤란드 비. 보레르 Ｊｎｋ 단백질 키나제의 억제제로서의 4-아릴옥신돌
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
AU767138B2 (en) 1998-12-17 2003-10-30 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
TR200101860T2 (tr) 1998-12-17 2001-12-21 F.Hoffmann-La Roche Ag Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
US6624171B1 (en) * 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
JP2002540096A (ja) * 1999-03-24 2002-11-26 スージェン・インコーポレーテッド キナーゼ阻害剤としてのインドリノン化合物
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
UA73976C2 (uk) * 2000-02-15 2005-10-17 Суджен, Інк. Заміщені піролом 2-індолінони, фармацевтична композиція, спосіб модуляції каталітичної активності протеїнкінази та спосіб лікування або профілактики захворювання, пов'язаного з протеїнкіназою
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US6737420B2 (en) 2000-03-23 2004-05-18 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US7034182B2 (en) 2000-06-30 2006-04-25 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US6633484B1 (en) 2000-11-20 2003-10-14 Intel Corporation Heat-dissipating devices, systems, and methods with small footprint
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2002096361A2 (en) 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
EP1401452A1 (en) 2001-06-27 2004-03-31 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in the treatment of alzheimer's disease
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
JP2005508953A (ja) 2001-10-10 2005-04-07 スージェン・インコーポレーテッド キナーゼ阻害剤としての３−［４−（置換ヘテロサイクリル）−ピロール−２−イルメチリデン］−２−インドリノン誘導体
US20040176372A1 (en) * 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
EA008865B1 (ru) * 2002-11-22 2007-08-31 Смитклайн Бичам Корпорейшн Производные 2-имино-4-оксотиазолидина
CN1894215B (zh) 2003-12-11 2012-03-21 得克萨斯州大学系统董事会 治疗细胞增殖疾病的化合物
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
CN100510679C (zh) * 2007-08-24 2009-07-08 中国北方车辆研究所 一种行星轮轴承试验装置
AU2009268841B2 (en) 2008-07-08 2014-02-06 Board Of Regents, The University Of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS)
JP2013510886A (ja) * 2009-11-16 2013-03-28 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア キナーゼ阻害剤
CN102115469A (zh) * 2011-03-21 2011-07-06 浙江大学 吲哚啉-2-酮类衍生物的制备和用途
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056790A (en) * 1960-01-08 1962-10-02 Wisconsin Alumni Res Found 8-ro-2-quinoline acrylic acid and lower alkyl esters thereof
DE3310891A1 (de) * 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
EP0304493B1 (en) * 1987-03-11 1992-09-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene derivatives
GB8727099D0 (en) * 1987-11-19 1987-12-23 Cellena Cell Eng A G Compositions containing melantonin/homologues
FI91062C (fi) * 1988-12-28 1994-05-10 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisten naftaleenijohdannaisten valmistamiseksi
GB9000950D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa New arylvinylamide derivatives and process for their preparation
GB9000939D0 (en) * 1990-01-16 1990-03-14 Erba Carlo Spa Improvement in the total synthesis of erbstatin analogs
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
GB9115160D0 (en) * 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation

Also Published As

Publication number Publication date
IE910664A1 (en) 1991-08-28
HU913626D0 (en) 1992-03-30
DE69115379D1 (de) 1996-01-25
EP0662473B1 (en) 1999-09-01
US5374652A (en) 1994-12-20
CA2053253C (en) 2005-04-26
HUT59081A (en) 1992-04-28
IL97049A (en) 1995-10-31
PT96897B (pt) 1998-07-31
EP0662473A1 (en) 1995-07-12
ES2137386T3 (es) 1999-12-16
JPH04506081A (ja) 1992-10-22
EP0470221A1 (en) 1992-02-12
DE69131581D1 (de) 1999-10-07
ATE131470T1 (de) 1995-12-15
NZ237182A (en) 1993-12-23
US5488057A (en) 1996-01-30
AU7241291A (en) 1991-09-18
IL97049A0 (en) 1992-03-29
WO1991013055A3 (en) 1991-10-31
US5627207A (en) 1997-05-06
JP3292845B2 (ja) 2002-06-17
CA2053253A1 (en) 1991-08-29
IE73666B1 (en) 1997-07-02
GB9004483D0 (en) 1990-04-25
ZA911441B (en) 1991-11-27
JP2000204070A (ja) 2000-07-25
GR3018891T3 (en) 1996-05-31
EP0470221B1 (en) 1995-12-13
HU210791B (en) 1995-07-28
ATE184000T1 (de) 1999-09-15
FI915010A0 (fi) 1991-10-23
DK0470221T3 (da) 1996-01-29
DE69115379T2 (de) 1996-05-15
AU652740B2 (en) 1994-09-08
ES2083569T3 (es) 1996-04-16
WO1991013055A2 (en) 1991-09-05
RU2091369C1 (ru) 1997-09-27
JP3152434B2 (ja) 2001-04-03
PT96897A (pt) 1991-10-31
DE69131581T2 (de) 2000-01-20

Similar Documents

Publication Publication Date Title
KR920701136A (ko) 아릴-및 헤테로아릴에테닐렌 유도체 및 이의 제조방법
EP0823413A3 (en) Benzoheterocyclic compounds
DK0595851T3 (da) Fremgangsmåde til fremstilling af sertralin-mellemprodukter
ES2059069T3 (es) Nuevos derivados de 1-alcoxi-(2-acilamino-etil)-naftalenos y su procedimiento de preparacion.
KR870000332A (ko) 이미다조헤테로 사이클릭 화합물의 제조방법
ES8300112A1 (es) Un procedimiento para preparar compuestos de cefem .
DK0674621T3 (da) Enantiomerer af carbazolderivater som 5-HT1-lignende agonister
MX9202975A (es) Nuevos compuestos biciclicos y sus sales farmaceuticamente aceptables y procedimiento para su preparacion.
GB1274973A (en) Acetylene derivatives
ES547071A0 (es) Procedimiento para la produccion de carbodiimidas substitui-das
KR960022476A (ko) 디페닐 디설파이드 화합물
ES8203870A1 (es) Procedimiento para preparar difenilbutil-1-acilpiperazinas
PT81314A (fr) Procede d'obtention de derives du thiadiazole actifs sur le systeme nerveux central
DK59693D0 (da) Fremgangsmaade til fremstilling af en 16,17-acetalsubstitueret androstan-17beta-(2-oxoethylenoxy)-forbindelse
ES543800A0 (es) Procedimiento de preparacion de nuevos derivados -etilben- zol con un grupo aminopropanolico sustituido y sus sales de adicion acidas y amonicas cuaternarias
DE3262166D1 (en) A new p-chlorophenoxyacetic acid derivative, its method of preparation and pharmaceutical composition
JPS53111078A (en) Carbostyril derivative
KR970042502A (ko) 새로운 아민고리 화합물
KR970042501A (ko) 새로운 아민고리 화합물
KR970042547A (ko) 새로운 퀴놀론 카르복실산 유도체 및 그 제조방법
TH4616B (th) อนุพันธ์ของควิโนลีน-3-คาร์บอกซิลิค แอซิตการเตรียมและการใช้สารเหล่านี้
KR960031439A (ko) 치환 인돌 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application